Kwon Chan-Young
Department of Oriental Neuropsychiatry, Dong-Eui University College of Korean Medicine, 52-57 Yangjeong-ro, Busanjin-gu, Busan 47227, Republic of Korea.
J Clin Med. 2022 Nov 28;11(23):7022. doi: 10.3390/jcm11237022.
In South Korea, with the highest suicide rate among Organization for Economic Co-operation and Development countries, doctors of both Korean medicine (KM) and Western medicine (WM) are licensed in the national healthcare system. The beneficial effects of complementary and integrative medicine, including KM, for depressive disorders, a major cause of suicide, have been reported in some clinical studies. Longitudinal change (2012-2021) of KM and WM use for depressive disorders and the attempts to scientificize KM in the context of depressive disorders were investigated. Specifically, clinical practice guidelines (CPGs) and national R&D projects of KM in the treatment of depressive disorders were investigated. The use of KM treatment for patients with a depressive disorder appears to be gradually decreasing in South Korea (annual number of patients in 2012 and 2021: 3607 and 2151 (-40.37%)), while the use of WM treatment is increasing (662,947 and 989,909 (+49.32%)). With the support of the government, KM CPG for depressive disorders and some R&D projects on KM for depressive disorders are being implemented. Our findings highlight the gap between the accumulation of clinical evidence, or the government's efforts to promote the evidence-based use of KM for depressive disorders, and its practical use in South Korea.
在经济合作与发展组织国家中自杀率最高的韩国,韩医(KM)和西医(WM)医生在国家医疗体系中均获许可。一些临床研究报告了包括韩医在内的补充与整合医学对抑郁症(自杀的主要原因之一)的有益效果。本研究调查了2012年至2021年期间韩医和西医用于治疗抑郁症的纵向变化情况,以及在抑郁症背景下将韩医科学化的尝试。具体而言,研究了韩医治疗抑郁症的临床实践指南(CPGs)和国家研发项目。在韩国,抑郁症患者使用韩医治疗的情况似乎在逐渐减少(2012年和2021年的患者年数量分别为3607例和2151例(-40.37%)),而西医治疗的使用则在增加(662,947例和989,909例(+49.32%))。在政府的支持下,针对抑郁症的韩医临床实践指南以及一些关于抑郁症的韩医研发项目正在实施。我们的研究结果凸显了韩国在临床证据积累、政府促进韩医循证治疗抑郁症的努力与其实际应用之间的差距。